Compare Home Depot Inc (HD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Home Depot Inc trades at $332.84 (market cap $332.08B), while Vertex Pharmaceuticals Incorporated trades at $480.36 (market cap $121.95B). The key difference: Home Depot Inc is far larger — about 2.7× Vertex Pharmaceuticals Incorporated's market cap, and Home Depot Inc pays a 2.8% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| HD | VRTX | |
|---|---|---|
Market Cap | $332.08B | $121.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $529.59 |
52-Week Low | $297.51 | $366.54 |
Enterprise Value | $393.64B | $116.69B |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $330.95, down 2.34% on the day, approaching its 52-week low amid broader market weakness in home improvement stocks. The company reported mixed quarterly earnings with a Q3 2025 miss but subsequent beats, while maintaining solid profitability with 8.41% net margins and strong ROE of 128.38%. Technical indicators show a bearish trend with key support at $321, while analysts maintain a predominantly bullish outlook with a $370.59 consensus price target representing 12% upside potential.
The outlook balances near-term headwinds from weakening big-ticket demand and rising mortgage rates against long-term strengths in Pro segment growth and housing market tailwinds. Investment opportunities include the stock's discount to analyst targets and resilient business model, while risks include margin pressure from investments, competitive threats, and sensitivity to housing market cycles.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
